DrugBiological
Siplizumab clinical trials
Also written MEDI-507 and TCD601.
- studies test it
- 26
- open now
- 4
- in phase 3
- 0
- first study started
- 1997
Keep track of what changes. Save the siplizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
26 studies that test it; most in 2023 (6)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1998 | 1 |
| 1999 | 2 |
| 2001 | 2 |
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2013 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 13
- Phase 2
- 16
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 9
ITB-Med LLC (8) · MedImmune LLC (8) · Massachusetts General Hospital (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · National Cancer Institute (NCI) (1) · Nefro Avillion Clinical Development, LLC (1) · University of Alabama at Birmingham (1) · Elizabeth C. Verna (1)
Often tested with
Tested in the same studies.
Rituximab (4) · Cyclophosphamide (3) · Abatacept (1) · Tacrolimus (1) · Adrenal Cortex Hormones (1) · Fludarabine (1)
Studies
Open first, then newest update. How each study uses siplizumab is read from its arms, and is right about nine times in ten.
Testing it · 26
- A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney TransplantRecruitingPhase 2Nefro Avillion Clinical Development, LLCNCT07508787Written as Siplizumab
- Delayed Tolerance Through Mixed ChimerismRecruitingPhase 1/2Massachusetts General HospitalNCT05900401Written as Siplizumab
- Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.RecruitingEarly Phase 1University of Alabama at BirminghamNCT06326476Written as Siplizumab
- A Study of SIPLIZUMAB in AILD and LT PatientsRecruitingPhase 1Elizabeth C. VernaNCT06455280Written as Siplizumab
- Siplizumab in T1DMTerminatedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT05574335Written as Siplizumab
- A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) PatientsTerminatedPhase 1ITB-Med LLCNCT06453668Written as TCD601
- A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)TerminatedPhase 2ITB-Med LLCNCT04803058Written as TCD601
- Siplizumab for Sickle Cell Disease TransplantTerminatedPhase 1/2Columbia UniversityNCT06078696Written as Siplizumab
- A Study of TCD601 in de Novo Renal Transplant RecipientsCompletedPhase 2ITB-Med LLCNCT05669001Written as TCD601
- A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal TransplantationTerminatedPhase 2ITB-Med LLCNCT06365437Written as TCD601
- A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)TerminatedPhase 2ITB-Med LLCNCT04803006Written as TCD601
- A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes PatientsTerminatedPhase 2ITB-Med LLCNCT06025110Written as TCD601
- A Dose Escalation Study in de Novo Renal TransplantationCompletedPhase 2ITB-Med LLCNCT04311632Written as TCD601
- A Study of TCD601 in the Induction of Tolerance in de Novo Liver TransplantationActive, not recruitingPhase 2ITB-Med LLCNCT06019507Written as TCD601
- Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasCompletedPhase 1National Cancer Institute (NCI)NCT01445535Written as Siplizumab
- Renal Allograft Tolerance Through Mixed ChimerismCompletedPhase 1/2Massachusetts General HospitalNCT01780454Written as MEDI-507
- Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesTerminatedPhase 2Massachusetts General HospitalNCT00113646Written as MEDI-507
- Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant RejectionCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00801632Written as MEDI-507
- Study of MEDI 507 in the Treatment of Pediatric PatientsCompletedPhase 1MedImmune LLCNCT00813618Written as MEDI-507
- A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft RejectionCompletedPhase 1MedImmune LLCNCT00807794Written as MEDI-507
Codes
What other systems call siplizumab · ClinicalTrials.gg INT005505
- MeSH (NLM) C544394siplizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) KUW1QG1ZM3SIPLIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7525805SiplizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C38685SiplizumabOne source FDA
- DrugBank DB06371One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C544394 | siplizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | KUW1QG1ZM3 | SIPLIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7525805 | Siplizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C38685 | Siplizumab | One source FDA |
| DrugBank | DB06371 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.